Cidara is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel anti-infectives that have the potential to transform the standard of care and save or improve patientsâ lives. Cidara is currently advancing its novel echinocandin antifungal, rezafungin acetate, in a Phase 3 clinical trial for the first-line treatment of candidemia and/or invasive candidiasis (ReSTORE). A second Phase 3 trial of once-weekly rezafungin for prophylaxis against invasive fungal infections in patients undergoing allogeneic blood and marrow transplantation (ReSPECT) is planned pending adequate funding and approval from the relevant regulatory authorities. In addition to its robust rezafungin clinical program, Cidara is applying its proprietary CloudbreakÂŽ platform to develop antiviral conjugates (AVCs) for the prevention and treatment of influenza and other viral diseases. The Cloudbreak platform is designed to discover compounds that both directly kill pathogens and direct a patientâs immune system to attack and eliminate pathogens. Cidara is headquartered in San Diego, California. Source
No articles found.
It was the middle of 2016 when we discovered that CBD could make a big difference ...
It was the middle of 2016 when we discovered th...
Corvus Pharmaceuticals is a clinical science-driven biopharmaceutical company. We ...
Corvus Pharmaceuticals is a clinical science-dr...
Alseres Pharmaceuticals, Inc. is focused on the development of diagnostic and ther...
Alseres Pharmaceuticals, Inc. is focused on the...
CUTERA, Inc. was founded in 1998 and is a global provider of Face + Body laser, li...
CUTERA, Inc. was founded in 1998 and is a globa...
OraSure Technologies is empowering the global community to improve health and well...
OraSure Technologies is empowering the global c...
Join the National Investor Network and get the latest information with your interests in mind.